Evidence map›Paper›PMID 36908285›Full record

ArticleGeburtshilfe und Frauenheilkunde2023

Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer.

Tanja N Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Milena Beierlein and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Geburtshilfe und Frauenheilkunde, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Tanja N FehmDepartment of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Manfred WelslauOnkologie Aschaffenburg, Aschaffenburg, Germany.
Volkmar MüllerDepartment of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Diana LüftnerImmanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany.
Florian SchützGynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany.
Peter A FaschingErlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Christoph ThomssenDepartment of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Isabell WitzelDepartment of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
Milena BeierleinErlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Erik BellevilleClinSol GmbH & Co. KG, Würzburg, Germany.
Michael UntchClinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany.
Marc ThillAgaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany.
Hans TeschOncology Practice at Bethanien Hospital, Frankfurt am Main, Germany.
Nina DitschDepartment of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany.
Michael P LuxKlinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.
Bahriye AktasDepartment of Gynecology, University of Leipzig Medical Center, Leipzig, Germany.
Maggie Banys-PaluchowskiDepartment of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Cornelia Kolberg-LiedtkeDepartment of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany.
Andreas D HartkopfDepartment of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
Achim WöckelDepartment of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.
Hans-Christian KolbergDepartment of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
Nadia HarbeckBreast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany.
Elmar StickelerDepartment of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

Indexed as

breast cancerchemotherapysurgerytherapy standard

Identifiers

PMID36908285
PMCPMC9998178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.